依达拉奉联合阿魏酸钠治疗急性脑梗死临床观察

Research on Edaravone combined with Sodium Ferulate in Treating Acute Infarction

目的探讨依达拉奉联合阿魏酸钠治疗急性脑梗死的临床疗效。方法 60例急性脑梗死患者随机分为对照组(30例)和治疗组(依达拉奉联合阿魏酸钠30例)。对照组采用基础治疗加复方丹参注射液;治疗组在基础治疗上加用依达拉奉和阿魏酸钠,疗程14d,于治疗前及治疗后用神经缺损情况评分[美国国立卫生院卒中量表(NIHSS)]、中风患者运动功能评分[简化FMA(SFMA)评分]及日常生活活动功能能力评分(ADL)进行疗效评价。结果治疗组治疗后NIH-SS、SFMA、ADL评分均较对照组有改善(P<0.05或P<0.01)。结论依达拉奉联合阿魏酸钠治疗急性脑梗死疗效肯定。

Objective To observe clinical application of Edaravone with Sodium Ferulate in treating acute infarction. Methods The patients were randomly divided into control group（30 cases） and treatment group（ Edaravone with Sodium Ferulate 30 cases）. The control group was treated with basic treatment and Compound Danshen injiection, the treatment group was treated with basic treatment and Edaravone with Sodium Ferulate. The treatment lasted for 14 days. The results evaluated through international index- uch as Nerve defect rate of U. S. National Institutes of Health Stroke Scale（NIHSS） ,Stroke patients with motor function score[ Simplify the FMA（SFMA） score] and activities of dally living score（ADL） before treatment and after Treatment. Results There was significant difference between treatment group and control group in NIHSS, SFMA, ADL（ P 〈 0. 05 or P 〈 0. 01 ） after treatment. Conclusion These results showed that treatment of Edaravone with Sodium Ferulate had superiority in treating acute iscbemic stroke.